Mammalian Synthetic Biology Approaches for the Precise Control of mAb N-Glycosylation (Pfizer-MIT PTM Track 2 Interim Joint Summary Document)
Invention type: Technology
/
Case number: #19972J
Disclosed herein are methods of generating proteoglycans with distinct glycan structures in engineered, non-naturally occurring eukaryotic cells. These methods make accessible a dynamic range of protein glycosylation. Compositions of engineered, non-naturally occurring cells capable of generating these proteoglycans are also disclosed herein.
Researchers
Timothy K Lu
/
Ron Weiss
/
Nevin Summers
/
Wen Tseng
/
Leonid Gaidukov
/
Michelle Chang
/
Giyoung Jung
/
Richard Cornell
/
Jeffrey Marshall
/
John Scarcelli
/
Bruno Figueroa
Departments: Department of Biological Engineering
Technology Areas: Biotechnology: Synthetic Biology / Drug Discovery and Research Tools: Genomics & Proteomics / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living
-
methods of glycoengineering proteoglycans with distinct glycan structures
United States of America | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.